Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring Revenue
Globe Newswire•30/10/2026•07:45 ET
0
Key Highlights
- ➤Allarity (ALLR) signs first revenue-generating CLIA laboratory services agreement
- ➤Services support European biotech’s U.S. precision oncology predictive device
- ➤Successful program could generate ongoing commercial testing and CLIA-related service revenue
- ➤Stenoparib remains Allarity’s top development priority
- ➤Allarity expects existing working capital to fund operations into summer 2028
Expert Statements
Thomas Jensen, Chief Executive Officer of Allarity Therapeutics
“This agreement moves our newly established CLIA laboratory services strategy into commercial execution, building on our existing gene expression and DRP® services business”
Thomas Jensen, Chief Executive Officer of Allarity Therapeutics
“For shareholders, the opportunity is to generate additional value from capabilities we have already built while maintaining stenoparib as our top development priority.”
- Agreement complements revenue from standard gene expression and DRP® services
- Development and validation services will support a European biotechnology company’s precision oncology predictive device for use in the United States
Get started
Create a free account to read the full story.